Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Terns Pharmaceuticals, Inc. - Common Stock (NQ:TERN)

7.500 -0.640 (-7.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,044,830
Open 7.720
Bid (Size) 7.070 (1)
Ask (Size) 7.460 (63)
Prev. Close 8.140
Today's Range 7.470 - 8.770
52wk Range 1.865 - 9.032
Shares Outstanding 61,071,897
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data?
Terns Pharmaceuticals announces 12-week Phase 2 results for oral obesity drug TERN-601, showing up to 4.6% weight loss but reporting cases of drug-induced liver injury. 
Via Benzinga
Netflix Posts Downbeat Earnings, Joins Aveanna Healthcare, Texas Instruments And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga

Performance

YTD
+32.3%
+32.3%
1 Month
-0.1%
-0.1%
3 Month
+23.8%
+23.8%
6 Month
+145.9%
+145.9%
1 Year
+7.3%
+7.3%

More News

Read More
Why Intuitive Surgical Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Which stocks are moving after the closing bell on Tuesday?
Via Chartmill
Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
2 Under-the-Radar Stocks That Could Soar
Via The Motley Fool
Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations
Via MarketMinute
Topics Economy
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
Via Benzinga
Terns (TERN) Q2 Net Loss Narrows 16%
Via The Motley Fool
Topics Intellectual Property
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street
Via The Motley Fool

Frequently Asked Questions

Is Terns Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Terns Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Terns Pharmaceuticals, Inc. - Common Stock trade on?
Terns Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Terns Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Terns Pharmaceuticals, Inc. - Common Stock is TERN on the Nasdaq Stock Market
What is the current price of Terns Pharmaceuticals, Inc. - Common Stock?
The current price of Terns Pharmaceuticals, Inc. - Common Stock is 7.500
When was Terns Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Terns Pharmaceuticals, Inc. - Common Stock was at 10/23/25 04:00 PM ET
What is the market capitalization of Terns Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Terns Pharmaceuticals, Inc. - Common Stock is 458.04M
How many shares of Terns Pharmaceuticals, Inc. - Common Stock are outstanding?
Terns Pharmaceuticals, Inc. - Common Stock has 458M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.